Laurie A. Farrell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laurie A. Farrell has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Robert E. Gerszten
Harvard Medical School
5 shared publications - Aarti Asnani
Beth Israel Deaconess Medical Center , Boston, Massachusetts
2 shared publications - Casie Curtin
CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA (A.L.B., A. Ariza, M.U., J.M.N.-P., C.C., Y.P., S.A., A.N.R.D., J.B., L.F., J.N.U., C.W.H., M.L., R.G., A. Asnani)
2 shared publications Jacob L. Barber
Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (U.A.T., J.L.B., G.T., L.F.).
2 shared publications- Abraham L. Bayer
Department of Immunology, School of Medicine (R.E., Z.R., C.K., S.S., A.L.B., P.A.), Tufts University, Boston, MA
1 shared publication - Abul Ariza Manzano
CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA (A.L.B., A. Ariza, M.U., J.M.N.-P., C.C., Y.P., S.A., A.N.R.D., J.B., L.F., J.N.U., C.W.H., M.L., R.G., A. Asnani)
1 shared publication
Latest Publications
- 27 August 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
Plasma Proteins Associated With the Immune Response to Anthracycline Cardiotoxicity in Patients With Hematologic Malignancies
BACKGROUND: Anthracyclines such as doxorubicin are well recognized to induce dose-dependent cardiotoxicity. However, traditional imaging and blood biomarkers of myocardial injury are inadequate for early risk stratification. We aimed to discover plasma proteins that correlate with the subsequent development of anthracycline-induced systolic dysfunction in patients, with validation studies in preclinical models. METHODS: We used an aptamer-based proteomics platform to measure over 7000 proteins in the plasma obtained at baseline (before anthracycline chemotherapy) in a prospectively enrolled cohort of patients with hematologic malignancies (n=34). The correlation between protein levels and change in left ventricular ejection fraction was assessed. Candidate biomarkers were validated in a second patient cohort treated with anthracyclines for hematologic malignancies (n=32), as well as in a mouse model of delayed doxorubicin cardiotoxicity. RESULTS: In both discovery and validation cohorts, baseline levels of CPVL (carboxypeptidase vitellogenic-like protein) and PIGR (poly immunoglobulin receptor) measured in the plasma before anthracycline treatment correlated with a subsequent decline in left ventricular ejection fraction (PIGR: R =−0.74; P =0.0022; CPVL: R =−0.74; P =0.0022). Findings were confirmed in human plasma samples using ELISA or Western blot, and similar changes in proteins were observed in mice treated with doxorubicin. In further support of PIGR as a biomarker representing the systemic adaptive immune response, doxorubicin treatment was associated with increased circulating levels of IgA + (immunoglobulin A) B cells in mice, which similarly correlated with the decline in left ventricular ejection fraction. The highest quartile of PIGR and CPVL levels was associated with decreased overall survival but not progression-free survival. CONCLUSIONS: Preanthracycline levels of the plasma immunologic proteins CPVL and PIGR were associated with a subsequent decline in cardiac function, representing potentially new inflammatory biomarkers of anthracycline cardiotoxicity.
- 27 August 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
Plasma Proteins Associated With the Immune Response to Anthracycline Cardiotoxicity in Patients With Hematologic Malignancies
BACKGROUND: Anthracyclines such as doxorubicin are well recognized to induce dose-dependent cardiotoxicity. However, traditional imaging and blood biomarkers of myocardial injury are inadequate for early risk stratification. We aimed to discover plasma proteins that correlate with the subsequent development of anthracycline-induced systolic dysfunction in patients, with validation studies in preclinical models. METHODS: We used an aptamer-based proteomics platform to measure over 7000 proteins in the plasma obtained at baseline (before anthracycline chemotherapy) in a prospectively enrolled cohort of patients with hematologic malignancies (n=34). The correlation between protein levels and change in left ventricular ejection fraction was assessed. Candidate biomarkers were validated in a second patient cohort treated with anthracyclines for hematologic malignancies (n=32), as well as in a mouse model of delayed doxorubicin cardiotoxicity. RESULTS: In both discovery and validation cohorts, baseline levels of CPVL (carboxypeptidase vitellogenic-like protein) and PIGR (poly immunoglobulin receptor) measured in the plasma before anthracycline treatment correlated with a subsequent decline in left ventricular ejection fraction (PIGR: R =−0.74; P =0.0022; CPVL: R =−0.74; P =0.0022). Findings were confirmed in human plasma samples using ELISA or Western blot, and similar changes in proteins were observed in mice treated with doxorubicin. In further support of PIGR as a biomarker representing the systemic adaptive immune response, doxorubicin treatment was associated with increased circulating levels of IgA + (immunoglobulin A) B cells in mice, which similarly correlated with the decline in left ventricular ejection fraction. The highest quartile of PIGR and CPVL levels was associated with decreased overall survival but not progression-free survival. CONCLUSIONS: Preanthracycline levels of the plasma immunologic proteins CPVL and PIGR were associated with a subsequent decline in cardiac function, representing potentially new inflammatory biomarkers of anthracycline cardiotoxicity.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (4) , e004924
Plasma Proteomics Reveals Dysregulated Pathways Across the Spectrum LMNA Cardiomyopathy
BACKGROUND: Pathogenic variants in the lamin A/C ( LMNA ) gene cause an aggressive form of dilated cardiomyopathy (DCM), marked by higher rates of advanced conduction disease, malignant ventricular tachyarrhythmias, and advanced heart failure compared with other causes of nonischemic cardiomyopathy. However, the mechanisms that drive the development and progression of LMNA DCM are incompletely understood. METHODS: To identify proteins and biological pathways associated with likely pathogenic/pathogenic LMNA variants, we measured ≈3000 plasma proteins using the OLINK platform in a genetic DCM cohort consisting of LMNA (n=41) and sarcomeric (n=18) DCM, along with phenotype-negative individuals from family-based cascade screening (n=55) with ( LMNA , n=16; sarcomere, n=12) or without the family variant (genotype negative, n=27). RESULTS: We identified several novel proteins associated with LMNA DCM compared with sarcomeric DCM, including EDA2R (ectodysplasin A2 receptor; per log2 fold change in relative protein abundance, β=3.0; P =4×10 − ³) and MYL4 (myosin light chain 4; β=2.32; P =5×10 − ³). Among the proteins associated with LMNA DCM, 26 showed concordant differential gene expression from single-cell sequencing in cardiomyocytes from myocardial biopsies in advanced LMNA heart failure compared with control hearts (false discovery rate, LMNA DCM and found the first principal component to be associated with left ventricular ejection fraction and complete heart block in the LMNA DCM cohort. Six proteins—EDA2R, MYL4, CRIM1 (cysteine-rich transmembrane bone morphogenetic protein regulator 1), TPR (translocated promoter region), FSTL3 (follistatin-like 3), and NFYA (nuclear transcription factor Y)—were associated with LMNA pathogenic variants across phenotype-negative individuals, DCM, and their respective cardiomyocyte RNA expression profiles in advanced heart failure. CONCLUSIONS: Proteomic profiling in individuals with likely pathogenic/pathogenic LMNA variants illuminated integral pathways across the spectrum of LMNA DCM. These findings may help advance genotype-driven biomarker discovery and tailored therapeutic development in LMNA DCM.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (4) , e004924
Plasma Proteomics Reveals Dysregulated Pathways Across the Spectrum LMNA Cardiomyopathy
BACKGROUND: Pathogenic variants in the lamin A/C ( LMNA ) gene cause an aggressive form of dilated cardiomyopathy (DCM), marked by higher rates of advanced conduction disease, malignant ventricular tachyarrhythmias, and advanced heart failure compared with other causes of nonischemic cardiomyopathy. However, the mechanisms that drive the development and progression of LMNA DCM are incompletely understood. METHODS: To identify proteins and biological pathways associated with likely pathogenic/pathogenic LMNA variants, we measured ≈3000 plasma proteins using the OLINK platform in a genetic DCM cohort consisting of LMNA (n=41) and sarcomeric (n=18) DCM, along with phenotype-negative individuals from family-based cascade screening (n=55) with ( LMNA , n=16; sarcomere, n=12) or without the family variant (genotype negative, n=27). RESULTS: We identified several novel proteins associated with LMNA DCM compared with sarcomeric DCM, including EDA2R (ectodysplasin A2 receptor; per log2 fold change in relative protein abundance, β=3.0; P =4×10 − ³) and MYL4 (myosin light chain 4; β=2.32; P =5×10 − ³). Among the proteins associated with LMNA DCM, 26 showed concordant differential gene expression from single-cell sequencing in cardiomyocytes from myocardial biopsies in advanced LMNA heart failure compared with control hearts (false discovery rate, LMNA DCM and found the first principal component to be associated with left ventricular ejection fraction and complete heart block in the LMNA DCM cohort. Six proteins—EDA2R, MYL4, CRIM1 (cysteine-rich transmembrane bone morphogenetic protein regulator 1), TPR (translocated promoter region), FSTL3 (follistatin-like 3), and NFYA (nuclear transcription factor Y)—were associated with LMNA pathogenic variants across phenotype-negative individuals, DCM, and their respective cardiomyocyte RNA expression profiles in advanced heart failure. CONCLUSIONS: Proteomic profiling in individuals with likely pathogenic/pathogenic LMNA variants illuminated integral pathways across the spectrum of LMNA DCM. These findings may help advance genotype-driven biomarker discovery and tailored therapeutic development in LMNA DCM.
- Open Access
- 19 June 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (8) , 100601
Plasma Proteomic Kinetics in Response to Acute Exercise
- 19 June 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (8) , 100601
Open AccessPlasma Proteomic Kinetics in Response to Acute Exercise
- Open Access
- 23 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (51) , eadc9245
Circulating hemopexin modulates anthracycline cardiac toxicity in patients and in mice
Anthracyclines such as doxorubicin (Dox) are effective chemotherapies, but their use is limited by cardiac toxicity. We hypothesized that plasma proteomics in women with breast cancer could identify new mechanisms of anthracycline cardiac toxicity. We measured changes in 1317 proteins in anthracycline-treated patients ( n = 30) and replicated key findings in a second cohort ( n = 31). An increase in the heme-binding protein hemopexin (Hpx) 3 months after anthracycline initiation was associated with cardiac toxicity by echocardiography. To assess the functional role of Hpx, we administered Hpx to wild-type (WT) mice treated with Dox and observed improved cardiac function. Conversely, Hpx −/− mice demonstrated increased Dox cardiac toxicity compared to WT mice. Initial mechanistic studies indicate that Hpx is likely transported to the heart by circulating monocytes/macrophages and that Hpx may mitigate Dox-induced ferroptosis to confer cardioprotection. Together, these observations suggest that Hpx induction represents a compensatory response during Dox treatment.
- 23 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (51) , eadc9245
Open AccessCirculating hemopexin modulates anthracycline cardiac toxicity in patients and in mice
Anthracyclines such as doxorubicin (Dox) are effective chemotherapies, but their use is limited by cardiac toxicity. We hypothesized that plasma proteomics in women with breast cancer could identify new mechanisms of anthracycline cardiac toxicity. We measured changes in 1317 proteins in anthracycline-treated patients ( n = 30) and replicated key findings in a second cohort ( n = 31). An increase in the heme-binding protein hemopexin (Hpx) 3 months after anthracycline initiation was associated with cardiac toxicity by echocardiography. To assess the functional role of Hpx, we administered Hpx to wild-type (WT) mice treated with Dox and observed improved cardiac function. Conversely, Hpx −/− mice demonstrated increased Dox cardiac toxicity compared to WT mice. Initial mechanistic studies indicate that Hpx is likely transported to the heart by circulating monocytes/macrophages and that Hpx may mitigate Dox-induced ferroptosis to confer cardioprotection. Together, these observations suggest that Hpx induction represents a compensatory response during Dox treatment.
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S79
Proteomic Profiles Of Left Ventricular Assist Device Implantation
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S79
Proteomic Profiles Of Left Ventricular Assist Device Implantation
- 21 September 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (40) , 25026-25035
Circulating testican-2 is a podocyte-derived marker of kidney health
In addition to their fundamental role in clearance, the kidneys release select molecules into the circulation, but whether any of these anabolic functions provides insight on kidney health is unknown. Using aptamer-based proteomics, we characterized arterial (A)-to-renal venous (V) gradients for >1,300 proteins in 22 individuals who underwent invasive sampling. Although most of the proteins that changed significantly decreased from A to V, consistent with renal clearance, several were found to increase, the most significant of which was testican-2. To assess the clinical implications of these physiologic findings, we examined proteomic data in the Jackson Heart Study (JHS), an African-American cohort (n = 1,928), with replication in the Framingham Heart Study (FHS), a White cohort (n = 1,621). In both populations, testican-2 had a strong, positive correlation with estimated glomerular filtration rate (eGFR). In addition, higher baseline testican-2 levels were associated with a lower rate of eGFR decline in models adjusted for age, gender, hypertension, type 2 diabetes, body mass index, baseline eGFR, and albuminuria. Glomerular expression of testican-2 in human kidneys was demonstrated by immunohistochemistry, immunofluorescence, and electron microscopy, while single-cell RNA sequencing of human kidneys showed expression of the cognate gene, SPOCK2, exclusively in podocytes. In vitro, testican-2 increased glomerular endothelial tube formation and motility, raising the possibility that its secretion has a functional role within the glomerulus. Taken together, our findings identify testican-2 as a podocyte-derived biomarker of kidney health and prognosis. Significance All existing blood biomarkers of kidney function such as creatinine and cystatin C undergo renal clearance and are thus inversely correlated with estimated glomerular filtrate rate (eGFR). Using a proteomic approach, we highlight the renal release of testican-2 among individuals undergoing invasive catheterization and show that higher blood testican-2 levels are associated with higher eGFR and slower rate of subsequent eGFR decline in two large racially diverse cohorts. In conjunction with microscopy and single-cell RNA sequencing of human kidney samples, these studies advance the concept that a protein released by the podocyte can provide insight into the kidney’s health and prognosis. Cell-based studies also raise the possibility that this protein has functional effects on neighboring glomerular endothelial cells.
- 21 September 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (40) , 25026-25035
Circulating testican-2 is a podocyte-derived marker of kidney health
In addition to their fundamental role in clearance, the kidneys release select molecules into the circulation, but whether any of these anabolic functions provides insight on kidney health is unknown. Using aptamer-based proteomics, we characterized arterial (A)-to-renal venous (V) gradients for >1,300 proteins in 22 individuals who underwent invasive sampling. Although most of the proteins that changed significantly decreased from A to V, consistent with renal clearance, several were found to increase, the most significant of which was testican-2. To assess the clinical implications of these physiologic findings, we examined proteomic data in the Jackson Heart Study (JHS), an African-American cohort (n = 1,928), with replication in the Framingham Heart Study (FHS), a White cohort (n = 1,621). In both populations, testican-2 had a strong, positive correlation with estimated glomerular filtration rate (eGFR). In addition, higher baseline testican-2 levels were associated with a lower rate of eGFR decline in models adjusted for age, gender, hypertension, type 2 diabetes, body mass index, baseline eGFR, and albuminuria. Glomerular expression of testican-2 in human kidneys was demonstrated by immunohistochemistry, immunofluorescence, and electron microscopy, while single-cell RNA sequencing of human kidneys showed expression of the cognate gene, SPOCK2, exclusively in podocytes. In vitro, testican-2 increased glomerular endothelial tube formation and motility, raising the possibility that its secretion has a functional role within the glomerulus. Taken together, our findings identify testican-2 as a podocyte-derived biomarker of kidney health and prognosis. Significance All existing blood biomarkers of kidney function such as creatinine and cystatin C undergo renal clearance and are thus inversely correlated with estimated glomerular filtrate rate (eGFR). Using a proteomic approach, we highlight the renal release of testican-2 among individuals undergoing invasive catheterization and show that higher blood testican-2 levels are associated with higher eGFR and slower rate of subsequent eGFR decline in two large racially diverse cohorts. In conjunction with microscopy and single-cell RNA sequencing of human kidney samples, these studies advance the concept that a protein released by the podocyte can provide insight into the kidney’s health and prognosis. Cell-based studies also raise the possibility that this protein has functional effects on neighboring glomerular endothelial cells.
- 19 June 2006
- Published by Wiley in European Journal of Neuroscience
- Vol. 23 (12) , 3171-3175
Huntingtin inclusions do not down‐regulate specific genes in the R6/2 Huntington's disease mouse
Transcriptional dysregulation is a central pathogenic mechanism in Huntington's disease (HD); HD and transgenic mouse models of HD demonstrate down-regulation of specific genes at the level of mRNA expression. Furthermore, neuronal intranuclear inclusions (NIIs) have been identified in the brains of R6/2 mice and HD patients. One possibility is that NIIs contribute to transcriptional dysregulation by sequestering transcription factors. We therefore assessed the relationship between NIIs and transcriptional dysregulation in the R6/2 mouse, using double-label in situ hybridization combined with immunohistochemistry, and laser capture microdissection combined with quantitative real-time PCR. There was no difference in transcript levels of specific genes between NII-positive and NII-negative neurons. These results demonstrate that NIIs do not cause decreases in D2, PPE and PSS mRNA levels in R6/2 striatum and therefore are not involved in the down-regulation of these specific genes in this HD model. In addition, these observations argue against the notion that NIIs protect against transcriptional dysregulation in HD.
- 19 June 2006
- Published by Wiley in European Journal of Neuroscience
- Vol. 23 (12) , 3171-3175
Huntingtin inclusions do not down‐regulate specific genes in the R6/2 Huntington's disease mouse
Transcriptional dysregulation is a central pathogenic mechanism in Huntington's disease (HD); HD and transgenic mouse models of HD demonstrate down-regulation of specific genes at the level of mRNA expression. Furthermore, neuronal intranuclear inclusions (NIIs) have been identified in the brains of R6/2 mice and HD patients. One possibility is that NIIs contribute to transcriptional dysregulation by sequestering transcription factors. We therefore assessed the relationship between NIIs and transcriptional dysregulation in the R6/2 mouse, using double-label in situ hybridization combined with immunohistochemistry, and laser capture microdissection combined with quantitative real-time PCR. There was no difference in transcript levels of specific genes between NII-positive and NII-negative neurons. These results demonstrate that NIIs do not cause decreases in D2, PPE and PSS mRNA levels in R6/2 striatum and therefore are not involved in the down-regulation of these specific genes in this HD model. In addition, these observations argue against the notion that NIIs protect against transcriptional dysregulation in HD.